The PPARγ agonist rosiglitazone attenuates acute kidney injury in septic rats [26], and another PPARγ agonist pioglitazone also attenuates cirrhosis-related renal dysfunction and chronic renal insufficiency caused by endotoxemia [27]. The gene discussed is PPARG; the disease is serum lipopolysaccharide activity.